Group: Record revenue, net income and clinical investment in 2016
• Group revenue up 21% to $216.1 million (2015: $178.2m);
• Net income attributable to Chi-Med up 46% to $11.7 million (2015: $8.0m), including $76.1 million in research and development expenses on an as adjusted basis (2015: $55.8m).
Innovation Platform: First successful pivotal Phase III outcome with launch now targeted for 2018
For full access, please click here.
